Abstract Details

Title Intravenous Immunoglobulins for the Prevention of Postpartum Relapses in Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P9 - Poster Session 9 (12:00 PM-1:00 PM)

Poster/Presentation
Number 9-001

Objective To evaluate the effect of intravenous immunoglobulins (IVIG) in the prevention of postpartum relapses in women with relapsing-remitting multiple sclerosis (RRMS).

Background Acute exacerbations may complicate the postpartum period in women with RRMS and there is still opposite evidence about the use of IVIG in the prevention of postpartum relapses in RRMS.

Design/Methods This was retrospective study performed in the University Hospital Center Ljubljana, Slovenia where the practice is for all women with RRMS who become pregnant to receive IVIG post delivery (10 g monthly, during first 6 months after delivery) and in the University Hospital Center Zagreb, Croatia, where no such practice exists. The following data were collected: date of delivery, age at delivery, year of the RRMS diagnosis, EDSS prior, during and after pregnancy, disease modifying therapy prior pregnancy, relapses in the year prior pregnancy, relapses during pregnancy, and relapses in the period of one year after pregnancy.

Results Data on 132 pregnancies from 112 women (mean age at delivery 31.70±4.10, average disease duration 6.34±4.33) were analyzed. Group that received IVIG had longer disease duration (7.58±5.00 vs. 5.19±3.23, p=0.001). There was no difference in other baseline characteristics between groups (p>0.05). There was no association between the IVIG treatment and annualized relapse rate one year after the delivery (0.26 vs 0.39, rate ratio 1.476, 95% CI 0.805-2.705, p=0.208). No risk factors for the postpartum relapse were identified (age at delivery, duration of RRMS, EDSS prior pregnancy, disease modifying therapy prior pregnancy, relapses in the year prior pregnancy, IVIG). We observed a decreased risk of relapse during pregnancy but significant rebound disease activity in the early postpartum period in the studied cohort of women with RRMS

Conclusions This study provides no evidence for postpartum administration of IVIG in women with RRMS.

Authors/Disclosures
Alenka Horvat Ledinek, MD (University Medical Center) PRESENTER	No disclosure on file
	No disclosure on file
Jana Jerse, MD (University Medical Center Ljubljana)	No disclosure on file
	No disclosure on file
	No disclosure on file
Tereza Gabelic	No disclosure on file
Barbara Barun	No disclosure on file
Ivan Adamec (University Hospital Center Zagreb)	Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sandoz. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zentiva. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jadran Galenski laboratorij. Ivan Adamec has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Phoenix farmacija.
Uros Rot, MD (University Medical Centre Ljubljana)	No disclosure on file
Sasa Sega Jazbec, MD, PhD (University Medical Center)	No disclosure on file
Magdalena Krbot Skoric	Magdalena Krbot Skoric has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
Mario Habek, MD (University of Zagreb, School of Medicine)	Dr. Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Dr. Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details